Table 5 The clinical trials of CAR-NK cell-based therapy for hematological malignancies and solid tumors
From: Natural killer cells: a promising immunotherapy for cancer
Cancer type | ClinicalTrials.gov Identifier | Initial time | Phase | N | Primary study endpoint |
|---|---|---|---|---|---|
R/R Non-Hodgkin Lymphoma | NCT04639739 CD19 | December 17, 2020 | Phase I | 9 | Incidence of dose limiting toxicity Incidence and severity of AEs and SAEs |
Relapsed and Refractory B Cell Lymphoma | NCT03692767 CD22 | March 2019 | Phase I | 9 | Occurrence of treatment related adverse events as assessed by CTCAE v4.0 |
Relapsed and Refractory B Cell Lymphoma | NCT03690310 CD19 | March 2019 | Phase I | 9 | Occurrence of treatment related adverse events as assessed by CTCAE v4.0 |
Epithelial Ovarian Cancer | NCT03692637 Mesothelin | March 2019 | Phase I | 30 | Occurrence of treatment related adverse events as assessed by CTCAE v4.0 |
metastatic Solid Tumours | NCT03415100 NKG2D-ligand | January 2, 2018 | Phase I | 30 | Number of Adverse Events |
Castration-Resistant Prostate Cancer | NCT03692663 PSMA | December 2018 | Phase I | 9 | Occurrence of treatment related adverse events as assessed by CTCAE v4.0 |
Solid Tumors | NCT03940820 ROBO1 | May 2019 | Phase I/II | 20 | Occurrence of treatment related adverse events as assessed by CTCAE v4.03 |
Relapse/Refractory MM | NCT03940833 BCMA | May 2019 | Phase I/II | 20 | Occurrence of treatment related adverse events as assessed by CTCAE v4.03 |
Recurrent/Metastatic Gastric or Head and Neck Cancer | NCT04847466 Irradiated PD-L1 | April 22, 2021 | Phase II | 55 | ORR |
Relapsed and Refractory B Cell Lymphoma | NCT03824964 CD19/CD22 | February 1, 2019 | Phase I | 10 | Occurrence of treatment related adverse events as assessed by CTCAE v4.0 |
B Lymphoid Malignancies | NCT04796675 CD19 | April 10, 2021 | Phase I | 27 | Incidence of Treatment-related Adverse Events |
Relapsed/Refractory CD33 + AML | NCT02944162 CD33 | October 2016 | Phase I/II | 10 | Adverse events attributed to the administration of the anti-CD33 CAR-NK cells |
CD19 Positive Leukemia and Lymphoma | NCT02892695 CD19 | September 2016 | Phase I | 10 | Adverse events attributed to the administration of the anti-CD19 CAR-NK cells |
Pancreatic Cancer | NCT03941457 ROBO1 | May 2019 | Phase I | 9 | Occurrence of treatment related adverse events as assessed by CTCAE v4.03 |
CD19 + Relapsed/Refractory Hematological Malignancies | NCT04796688 CD19 | March 10, 2021 | Phase I | 27 | Incidence of Treatment-related Adverse Events |
Relapsed/Refractory B-Lymphoid Malignancies | NCT03056339 CD19 | June 21, 2017 | Phase I/II | 36 | Toxicity and efficacy |